New Cutting-Edge Report on Ophthalmology Therapeutics Market Published by MarketPublishers.com

10 Oct 2011 • by Natalie Aster
New Cutting-Edge Report on Ophthalmology Therapeutics Market Published by MarketPublishers.com

LONDON – The global ophthalmology market is expected to increase from last year’s USD 10.3 billion to USD 13.2 billion by 2017, growing at 3.6% CAGR. The introduction of new molecules, which are currently in the regulatory filing stage as well as in the later stages of development, will drive the market growth.

New report “Ophthalmology Therapeutics Market to 2017 - Protein Kinase Inhibitors and Prostaglandin H-Synthase Inhibitors to Drive Diabetic Retinopathy Market” prepared by GBI Research has been recently published by Market Publishers Ltd.

Report Details:

Title: Ophthalmology Therapeutics Market to 2017 - Protein Kinase Inhibitors and Prostaglandin H-Synthase Inhibitors to Drive Diabetic Retinopathy Market
Published: October, 2011
Pages: 156
Price: US$ 3,500.00

The report provides true insights into the current and future state of the world ophthalmology therapeutics market, detailing six therapeutic indications of ophthalmology - glaucoma, allergic conjunctivitis, dry eye syndrome, diabetic macular edema, diabetic retinopathy and wet age macular degeneration. It examines global ophthalmology treatment usage patterns for the aforementioned indications and gives insights into the ophthalmology therapeutics R&D product pipeline. Furthermore, drivers and restrains, competitive landscape, key M&A activities and licensing agreements are also featured.

Report Contents:

1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures

2 GLOBAL OPHTHALMOLOGY MARKET - INTRODUCTION
2.1 Overview
2.2 GBI Research Report Guidance

3 GLOBAL OPHTHALMOLOGY MARKET - MARKET CHARACTERIZATION
3.1 Introduction
3.2 Revenue Forecast for the Global Ophthalmology Market
  3.2.1 Revenues
  3.2.2 Annual Cost of Treatment (ACT)
3.3 Branded and Generic Market Share
3.4 Treatment Usage Patterns
  3.4.1 Diseased Population
  3.4.2 Treatment Seeking Population
  3.4.3 Diagnosed Population
  3.4.4 Prescription Population

4 GLOBAL OPHTHALMOLOGY MARKET - GEOGRAPHICAL LANDSCAPE
4.1 The US
  4.1.1 Revenue
  4.1.2 Annual Cost of Treatment
  4.1.3 Treatment Usage Pattern
4.2 Top Five European Countries
  4.2.1 Revenues of the Top Five European Countries
  4.2.2 Annual Cost of Treatment
  4.2.3 Treatment Usage Pattern
4.3 Japan
  4.3.1 Revenues
  4.3.2 Annual Cost of Treatment
  4.3.3 Treatment Usage Pattern

5 GLOBAL OPHTHALMOLOGY MARKET - GLAUCOMA THERAPEUTICS MARKET
5.1 Introduction
5.2 Global Market Forecasts
5.3 Annual Cost of Treatment
5.4 Branded and Generic Market Share
5.5 Treatment Flow Algorithm
5.6 Treatment Usage Patterns
5.7 Market Forecasts for The US
5.8 Market Forecasts for the Top Five European Countries
5.9 Market Forecasts for Japan
5.10 Drivers of the Glaucoma Market
  5.10.1 Increasing Prevalence of Eye Diseases
  5.10.2 Improved Diagnosis of the Disease
5.11 Restraints for Glaucoma Market
  5.11.1 Lower Awareness and Treatment Seeking Rates
  5.11.2 Patent Expiry of Major Glaucoma Drugs such as Xalatan and Alphagan will Result in Negative Growth

6 GLOBAL OPHTHALMOLOGY MARKET - ALLERGIC CONJUNCTIVITIS
6.1 Introduction
  6.1.1 Seasonal Allergic Conjunctivitis (SAC)
  6.1.2 Perennial Allergic Conjunctivitis (PAC)
6.2 Market Forecasts
6.3 Annual Cost of Treatment
6.4 Branded and Generic Market Share
6.5 Treatment Flow Algorithm
6.6 Treatment Usage Patterns
6.7 Market Forecasts for the US
6.8 Market Forecasts for the Top Five European Countries
6.9 Market Forecasts for Japan
6.10 Drivers of Allergic Conjunctivitis Market
  6.10.1 Increasing Awareness
6.11 Restraints for Allergic Conjunctivitis Market
  6.11.1 Series of Patent Expires will Result in Slower Market Growth

7 GLOBAL OPHTHALMOLOGY MARKET - WET AGE MACULAR DEGENERATION
7.1 Introduction
7.2 Global Market Forecasts
7.3 Annual Cost of Treatment
7.4 Branded and Generic Market Share
7.5 Treatment Flow Algorithm
7.6 Treatment Usage Patterns
7.7 Market Forecasts for the US
7.8 Market Forecasts for the Top Five European Countries
7.9 Market Forecasts for Japan
7.10 Drivers of Macular Degeneration Market
  7.10.1 Elderly Population to Drive Macular Degeneration Population
  7.10.2 Active Research and Development Efforts will Drive Market
  7.10.3 Improvements in Diagnostic Tools will Increase the Diagnosed Population
7.11 Restraints for Macular Degeneration Market
  7.11.1 Extremely Poor Treatment Seeking Rates Especially for Wet Macular Degeneration will Result in Very Small Potential Customer Segment
  7.11.2 Increasing Off Label Use of Cheaper Drugs will Impact Annual Cost of Therapy

8 GLOBAL OPHTHALMOLOGY MARKET - DIABETIC MACULAR EDEMA
8.1 Introduction
8.2 Global Market Forecasts
8.3 Annual Cost of Treatment
8.4 Branded and Generic Market Share
8.5 Treatment Flow Algorithm
8.6 Treatment Usage Patterns
8.7 Market Forecasts for The US
8.8 Market Forecasts for the Top Five European Countries
8.9 Market Forecasts for Japan
8.10 Drivers of the Diabetic Macular Edema Market
  8.10.1 Increasing Prevalence of Conditions Such as Diabetes will Drive the Market
  8.10.2 Improved Awareness will Drive Volumes
8.11 Restraints for Macular Edema Market
  8.11.1 Availability of Effective Alternative Options Such as Laser Treatment

9 GLOBAL OPHTHALMOLOGY MARKET - DRY EYE SYNDROME
9.1 Introduction
9.2 Global Market Forecasts
9.3 Annual Cost of Treatment
9.4 Branded and Generic Market Share
9.5 Treatment Flow Algorithm
9.6 Treatment Usage Patterns
9.7 Market Forecasts for the US
9.8 Market Forecasts for the Top Five European Countries
9.9 Market Forecasts for Japan
9.10 Drivers for the DES Therapeutics Market
  9.10.1 Increase in Prevalence
9.11 Barriers for the DES Therapeutics Market
  9.11.1 Low Treatment Seeking Rate
  9.11.2 Inadequate Treatment Options

10 GLOBAL OPHTHALMOLOGY MARKET - DIABETIC RETINOPATHY
10.1 Introduction
10.2 Global Market Forecasts
10.3 Annual Cost of Treatment
10.4 Branded and Generic Market Share
10.5 Treatment Flow Algorithm
10.6 Treatment Usage Patterns
10.7 Market Forecasts for The US
10.8 Market Forecasts for the Top Five European Countries
10.9 Market Forecasts for Japan
10.10 Drivers for the DR Therapeutics Market
  10.10.1 Diabetic Population Growth
  10.10.2 Advancement of Innovative Targeted Therapies
10.11 Barriers for the DR Therapeutics Market
  10.11.1 Low Prescription Rates
  10.11.2 Late Stage Diagnosis

11 GLOBAL OPHTHALMOLOGY MARKET - PIPELINE ANALYSIS
11.1 Introduction
11.2 Glaucoma - Research and Development Pipeline
  11.2.1 Overview
  11.2.2 Pipeline by Clinical Phases of Development
11.3 Diabetic Macular Edema - Research and Development Pipeline
  11.3.1 Overview
  11.3.2 Pipeline by Clinical Phases of Development
11.4 Wet Aged Macular Degeneration - Research and Development Pipeline
  11.4.1 Overview
  11.4.2 Pipeline by Clinical Phases of Development
11.5 Allergic Conjunctivitis - Research and Development Pipeline
  11.5.1 Overview
  11.5.2 Pipeline by Clinical Phases of Development
11.6 Dry Eye Syndrome - Research and Development Pipeline
  11.6.1 Overview
  11.6.2 Pipeline by Clinical Phases of Development
11.7 Diabetic Retinopathy - Research and Development Pipeline
  11.7.1 Overview
  11.7.2 Pipeline by Clinical Phases of Development

12 PROFILES OF PROMISING DRUGS IN OPHTHALMOLOGY THERAPEUTICS MARKET
12.1 Glaucoma
  12.1.1 Tafluprost (Saflutan)
  12.1.2 NCX-116 (Formerly PF-03187207)
12.2 Diabetic Macular Edema
  12.2.1 Macugen (Pegaptanib Sodium)
  12.2.2 Iluvien (Fluocinolone Acetonide)
  12.2.3 iCo-007
12.3 Wet Age Macular Degeneration
  12.3.1 VEGF Trap-Eye
12.4 Allergic Conjunctivitis
  12.4.1 SCH 697243
  12.4.2 Grass Pollen Allergoid
  12.4.3 SAR 1118
12.5 Dry Eye Syndrome
  12.5.1 Rebamipide (OPC-12759E)
  12.5.2 CF101
  12.5.3 Remura (Bromfenac)
  12.5.4 Tasocitinib (CP-690550)
12.6 Diabetic Retinopathy
  12.6.1 Lucentis (Ranibizumab)
  12.6.2 Macugen (Pegaptanib Sodium)
  12.6.3 Arxxant (Ruboxistaurin)
  12.6.4 Vitreosolve
  12.6.5 Nevanac (Nepafenac Ophthalmic)

13 GLOBAL OPHTHALMOLOGY MARKET - COMPETITIVE LANDSCAPE
13.1 Company Profiles for Ophthalmology
  13.1.1 Pfizer
  13.1.2 Allergan, Inc.
  13.1.3 Alcon, Inc.
  13.1.4 Novartis AG
  13.1.5 Merck & Co Inc
  13.1.6 Roche

14 GLOBAL OPHTHALMOLOGY MARKET - STRATEGIC CONSOLIDATIONS
14.1 Mergers and Acquisitions
  14.1.1 Overview
  14.1.2 Major Mergers and Acquisitions Deals
  14.1.3 Segmentation by Geography
  14.1.4 Segmentation by Deal Value
14.2 Co-development Deals
  14.2.1 Major Co-development Deals
  14.2.2 Segmentation by Geography
14.3 Licensing Deals
  14.3.1 Major Licensing Deals
  14.3.2 Segmentation by Geography
  14.3.3 Segmentation by Value

15 GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET - APPENDIX
15.1 Market Definitions
15.2 Abbreviations
15.3 Research Methodology
  15.3.1 Coverage
  15.3.2 Secondary Research
  15.3.3 Primary Research
15.4 Therapeutic Landscape
  15.4.2 Market Size by Geography
15.5 Geographical Landscape
15.6 Pipeline Analysis
15.7 Competitive Landscape
  15.7.1 Expert Panel Validation
15.8 Contact Us
15.9 Disclaimer
15.10 Sources

LIST OF TABLES

LIST OF FIGURES

COMPANIES MENTIONED
Pfizer
Allergan, Inc.
Alcon, Inc.
Novartis AG
Merck & Co Inc
Roche

Reports Examining other Medicine, Pharmaceuticals & Biotechnology Markets are also Available:

  • Clinical Trial Recruitment in Dermatology - Most Trials Focus on Atopic Dermatitis While Acne Vulgaris Has Highest Patient Numbers
  • Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
  • Contraceptives Market to 2017 - Hormonal Contraceptives and Strong Pipeline to Drive the Growth in Future
  • HIV/AIDS Therapeutics Market to 2017 - Superior Combination Therapies and Decreasing Mortality to Sustain Market Growth Despite Major Patent Expiries
  • Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value

More new reports by the publisher can be found at GBI Research page.

 

CONTACTS

The Market Publishers, Ltd.

Mrs. Tanya Rezler

Tel: +44 208 123 2220

Fax: +44 207 900 3970

ps@marketpublishers.com

www.MarketPublishers.com